Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYXIN versus CORDRAN N.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYXIN versus CORDRAN N.
CHLOROMYXIN vs CORDRAN N
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloromyxin is a combination product of chloramphenicol and polymyxin B. Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides in gram-negative bacteria.
Cordran N contains flurandrenolide, a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive actions by inducing phospholipase A2 inhibitory proteins (lipocortins) and modulating gene expression; neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
500 mg IV every 6 hours or 1 g IV every 12 hours; infusion over 30 minutes.
Apply sparingly to affected area 2-3 times daily. Use for no longer than 2 weeks.
None Documented
None Documented
CHLOROMYXIN is not a recognized drug. No data available.
Approximately 1-2 hours. Short half-life consistent with topical use; systemic exposure minimal with proper application.
CHLOROMYXIN is not a recognized drug. No data available.
Primarily renal (biliary/fecal minimal). Unchanged drug and glucuronide metabolites excreted in urine.
Category C
Category C
Antibiotic
Topical Corticosteroid + Antibiotic